RxDoctor Payments Data

Cynthia Behling

Anatomic Pathology & Clinical Pathology · San Diego, CANPI 1063476331

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,625 of the $7,126 with a category attached, or 78.9%. Novo Nordisk AS accounts for 78.9% of it on its own, with 2 other manufacturers making up the rest.

$7,126in general payments, 2019–2025

Across 4 payments — averaging $1781.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$6K
  • Pfizer$1K
  • Eli Lilly$21
$1,797,476in research payments, 2019–2025

Across 207 payments — averaging $8683.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$910K
  • Ventana Medical Systems, Inc.$620K
  • Boehringer Ingelheim International GmbH$181K
  • Hologic Inc$43K
  • Cytyc Corporation$43K
  • Eli Lilly$117

What the payments were for

  • Consulting fees$5,62579%
  • Speaking & faculty fees$1,48021%
  • Food & beverage$210%

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS2$5,625
Pfizer1$1,480
Eli Lilly1$21

How this compares

$7,126 in reported general payments places this provider in the 85th percentile of 814 anatomic pathology & clinical pathology providers in California.

See all anatomic pathology & clinical pathology providers in California

Other anatomic pathology & clinical pathology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →